ECOG E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Objective

E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with AIs due to the development of musculoskeletal symptoms (MSS). Women with stage 1-111 breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join.

https://www.clinicaltrials.gov/ct2/show/NCT01824836

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.

Last Updated: 06/04/2018

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Breast Cancer